Analyst Reco. Qiagen N.V. Xetra

Equities

Market Closed - Xetra Other stock markets 11:35:25 2024-05-17 am EDT			5-day change	1st Jan Change
42.14 ^EUR	+0.13%		+3.11%	+3.75%

May. 15	Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	MT
May. 14	QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	CI

QIAGEN NV : Berenberg reaffirms its Buy rating	Apr. 30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	Apr. 30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 30	ZD
QIAGEN NV : Jefferies remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS sticks Neutral	Apr. 30	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 16	ZD
QIAGEN NV : UBS reaffirms its Neutral rating	Mar. 01	ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	Feb. 16	MT
QIAGEN NV : Berenberg reiterates its Buy rating	Feb. 16	ZD
QIAGEN NV : Deutsche Bank remains its Buy rating	Feb. 14	ZD
QIAGEN NV : JP Morgan reiterates its Buy rating	Feb. 08	ZD
QIAGEN NV : UBS reiterates its Neutral rating	Feb. 08	ZD
QIAGEN : In line Q4; routine business prospects remain intact	Feb. 07
QIAGEN NV : Gets a Neutral rating from UBS	Feb. 07	ZD
QIAGEN NV : Berenberg reaffirms its Buy rating	Feb. 07	ZD
QIAGEN NV : DZ Bank gives a Buy rating	Feb. 07	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Feb. 07	ZD
BofA Securities Raises Price Target on Qiagen to $55 From $52, Maintains Buy Rating	Jan. 29	MT

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am EDT